Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

MHRA approves Leqselvi (deuruxolitinib) targeting JAK kinases for severe alopecia areata treatment
Small molecule, autoimmune, JAK inhibitor, alopecia areata, JAK1/JAK2/TYK2 - Read more

Enodia Therapeutics pays for Kezar Life Sciences preclinical protein degrader program - $1M upfront + $127M milestones
Acquisition, small molecule, protein degradation, milestone payments - Read more

PRISM BioLab, Receptor.AI collaborate on AI-guided small molecule discovery platform targeting intracellular proteins
Research collaboration, AI/ML, small molecule, drug discovery, metabolic diseases - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Ultragenyx Pharmaceutical's DTX301 (avalotcagene ontaparvovec) hits Ph3 primary endpoint for ornithine transcarbamylase deficiency
Gene therapy, metabolic, AAV vector, ornithine transcarbamylase deficiency, urea cycle disorder - Read more

Capricor Therapeutics' Deramiocel shows significant cardiac and functional benefits in Ph3 Duchenne muscular dystrophy trial
Cell therapy, neurological, Duchenne muscular dystrophy, cardiac function - Read more

Regenxbio reports positive Ph1/Ph2 data for RGX-202 gene therapy in Duchenne muscular dystrophy
Gene therapy, neurological, Duchenne muscular dystrophy, AAV vector, muscle targeting - Read more

Indivior Pharmaceuticals prices $450M convertible notes offering for debt repayment, share buybacks
Addiction medicine, specialty pharmaceuticals - Read more

Eli Lilly invests $126M to expand Japan manufacturing plant for diabetes and obesity medicines
Diabetes/obesity therapies, metabolic disorders, operational, major transaction, strategic - Read more

Rare disease drug sales projected to exceed $400B by 2032 despite FDA regulatory challenges
Orphan drugs, rare disease, financial, revenue impact - Read more

Small molecules comprise 45% of top 20 orphan drugs in development, showing resurgence in R&D
Small molecule, rare disease, strategic, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Pfizer shuts down Ignite biotech incubation program, $41M revenue unit wound down
Incubation program, R&D services, antibody, platform technology - Read more

Novo Holdings' assets fell 34% to €93B ($107.3B) as Novo Nordisk struggled in obesity market
GLP-1 agonist, obesity, financial, major transaction - Read more

Vistagen Therapeutics lays off 20% of staff to focus resources on struggling social anxiety candidate fasedienol
Nasal spray, neurological, cost reduction, operational - Read more

Eli Lilly warns compounded tirzepatide contains concerning impurities from vitamin B12 reactions with unknown health effects
Peptide hormone, diabetes, competitive, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here